idea-014 · human · wrapped
Read this before anything else on the page. A low count here is usually a
statement about this repo's tooling rather than about the idea — a
unconfirmed reimbursement claim most often means the CMS cache file
is absent and nothing was searched, which is not evidence that a code
does not exist.
The packet a human reads. See docs/wrap-spec.md. This section says nothing about whether the idea is good — it says the file is finished enough to be read, and names what to do next. Filling it in advances no candidate and approves nothing.
The one-paragraph version. This is a small handheld device, connected by Bluetooth to a phone app, that a child with persistent asthma (ages 5-17) would use at home once a day: it measures how well their lungs are working (peak flow / FEV1) and asks a few questions about symptoms and whether they took their medication, then sends all of it to their prescribing doctor. It would be sold by prescription only, not over the counter, specifically so the doctor's practice can bill Medicare-style monitoring codes for reviewing that data between office visits — that billing angle, not new hardware, is the whole idea. The underlying measurement technology already exists in several FDA-cleared devices; what doesn't yet exist is a device positioned this way, for this population, tied this explicitly to between-visit billing.
What would have to be true. One line per lens, quoted verbatim from that deck's load-bearing condition. Do not summarise or re-rank them.
device_class field
itself states neither has been confirmed by a classification lookup."
Cheapest next test: a PATENTSVIEW-backed patent search for claims covering connected peak-flow/spirometry devices combined with RPM-eligible data transmission and asthma-action-plan-threshold alerting logic (Scores table, FTO/IP row) — FTO is one of only four factors the Stage 5 gate depends on and is currently entirely unexamined (no PATENTSVIEW_API_KEY set in this environment), a keyword landscape search is comparatively cheap next to the CMS-file and CDC-table work already done for other factors, and a single finding here (a live blocking patent) is the one result that could kill this candidate outright regardless of every other score.
Where the evidence actually stands. Per wrap_status.py: 8 of 9 rubric factors carry either a score or a named evidence gap (Strategic fit is the one factor with no claim speaking to it at all, verified or otherwise); all 4 of the 4 gate-relevant core factors (Regulatory, Reimbursement, TAM, FTO/IP) are accounted for, though FTO/IP is accounted for by being explicitly named as unexamined, not resolved. Of 31 claims total: 14 verified, 11 unconfirmed, 6 unverified (the decks' own unbacked-assumption write-backs, claims 26-31). Two things are blocked on tooling, not on a finding, and should not be read as evidence against the idea: (1) FTO/IP — no PATENTSVIEW_API_KEY/EPO OPS credentials are configured in this environment, so "unexamined" means literally that, not "searched and clear"; (2) the hcpcs/payment/coverage connectors still return unconfirmed for the RPM CPT codes because this repo has no local rate-cache file — the actual CMS payment amounts were instead retrieved directly from CMS's own CY2026 PFS National Payment Amount File by the research lane and are verified (claims 16-18), so this is a stale connector gap, not an open question. Set against that: the strongest verified evidence in the file (Regulatory, Reimbursement, Mechanism) all rests on primary sources fetched directly (openFDA, CMS, peer-reviewed literature, ClinicalTrials.gov) rather than vendor-blog or web-search summaries — a materially stronger evidentiary base than the candidate started with at Stage 2.
| Intended use | For prescription use by children and adolescents ages 5 through 17 with; physician-diagnosed persistent asthma, to record and transmit daily peak expiratory flow; and/or FEV1 measurements together with structured symptom and medication-adherence data from; the home to the prescribing clinician, as an adjunct to guideline-directed asthma; action-plan management and not for use in acute respiratory distress or as a substitute for; emergency care. |
|---|---|
| Mechanism | A handheld, Bluetooth-connected electronic peak-flow meter (and/or spirometer) paired; with a smartphone app that logs daily peak expiratory flow and/or FEV1 readings alongside a; structured symptom-and-medication-adherence questionnaire, transmits the combined record to; the prescribing clinician's remote-physiologic-monitoring (RPM) workflow, and flags readings; that cross a patient-specific asthma-action-plan threshold for clinician review between; visits. |
| Device class | # Two live routes on the same hardware concept, most likely first.; Class II — 510(k) — 21 CFR 868.1840 (diagnostic spirometer), product code BZG — read from; the K183479 "Asthma Monitor AM3 G+" 510(k) summary, which the Generator found described as; a combined lung-function-plus-symptom/medication-questionnaire device for home and clinical; use. Most likely route because it is the closer functional predicate.; Class II — 510(k) — 21 CFR 868.1860 (peak flow meter), product code BZH (product code read; off a third-party FDA-search-tool URL, not off an FDA record directly, and is flagged as; weaker for that reason) — the route if FDA reads the connected peak-flow-only hardware and; the tracking app as functionally separate submissions, using a bare peak-flow-meter; predicate such as K200832 or K230423 for the hardware and treating the app as accessory; software. |
| Predicate or analog | K183479 "Asthma Monitor AM3 G+" (closest functional analog — combined; spirometer + symptom/medication questionnaire, home and clinical use, cleared 2019 per web; search of the FDA 510(k) summary; Generator has not opened the underlying PDF directly). Also; identified as bare peak-flow-meter analogs, not combined-function: K200832 "Safey Peak Flow; Meter" (predicate cited in that filing: K181666 "Smart One") and K230423 "Electronic Peak; Flow Meter" (Taian Dalu). No device combining connected peak-flow/spirometry, symptom; tracking, and an RPM-specific pediatric-asthma indication was identified — that combination; is the candidate's proposed indication-scope narrowing, not a claim that such a combined; device already exists. |
| Launch jurisdiction | US |
| Target | human |
| Factor | Score | What would settle it |
|---|---|---|
| Regulatory pathway | 3 | openFDA classification lookup (classification --product-code BZG and --product-code BZH) plus a direct read of the K183479 510(k) summary PDF at accessdata.fda.gov/cdrh_docs/pdf18/K183479.pdf to settle which predicate route governs. |
| Reimbursement pathway | 2 | CMS Physician Fee Schedule Look-Up Tool for the 2026 non-facility rates on 99453/99454/99457, and a search for any Medicare LCD/NCD or named commercial-payer coverage policy addressing home RPM for pediatric asthma monitoring. |
| TAM | 2 | Primary CDC/NHIS table (not a web-search summary) breaking out persistent vs. intermittent pediatric asthma prevalence; a published claims/registry-based estimate of RPM enrollment or prescribing rates to test the 30-40% addressable-share…the rest of this gap analysisassumption. |
| FTO / IP | 2 | PATENTSVIEW-backed patent search for claims covering connected peak-flow/spirometry devices combined with RPM-eligible data transmission and asthma-action-plan-threshold alerting logic. |
| Moat / defensibility | 2 | Search for other prescription-only, RPM-billed pediatric-asthma monitors already marketed or in 510(k)/FDA pipeline, to see how contested this exact positioning already is. |
| Mechanism & clinical risk | 4 | Published validation literature comparing home electronic peak-flow/spirometry accuracy to in-clinic spirometry in the 5-17 age range, to confirm no unusual accuracy or false-alert risk for this specific use case. |
| Capital intensity & time-to-revenue | 3 | A cost/timeline benchmark for a comparable Class II connected-respiratory-device 510(k) submission (e.g., a device-consulting estimate or a comparable public company's S-1/10-K R&D disclosures). |
| Competitive intensity | 2 | openFDA 510(k) pull for all recently cleared connected peak-flow/spirometer devices carrying RPM-billing marketing claims, plus a funding-database (Crunchbase/Pitchbook) search for recent raises or launches in this niche. |
| Strategic fit & portfolio balance | — | An internal portfolio inventory (not a public source) showing where this would sit relative to current hero bets vs. cash-generative spokes. |
All six wrap criteria are met.
Domain dossier: pediatric-persistent-asthma-home-monitoring
Source file: knowledge-base/candidates/idea-014.md
Nothing on this page is a recommendation. Shortlist review, legal and clinical sign-off and capital allocation are human-only decisions, and no agent in this repo may make or simulate one. This is a compilation of what the candidate file says.